356 related articles for article (PubMed ID: 28730640)
1. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
[TBL] [Abstract][Full Text] [Related]
2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
[TBL] [Abstract][Full Text] [Related]
3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
4. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
Bombardier C; Hazlewood GS; Akhavan P; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Gardam MA; Askling J; Bykerk V;
J Rheumatol; 2012 Aug; 39(8):1583-602. PubMed ID: 22707613
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
Favalli EG; Caporali R; Sinigaglia L; Pipitone N; Miniati I; Montecucco C; Matucci-Cerinic M;
Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S15-27. PubMed ID: 21906424
[TBL] [Abstract][Full Text] [Related]
6. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K; Krüger K; Wollenhaupt J; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester GR; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
Rheumatol Int; 2014 Jan; 34(1):1-9. PubMed ID: 23942828
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
Caporali R; Conti F; Alivernini S; Atzeni F; Seriolo B; Cutolo M; Valesini G; Ferraccioli G; Sarzi-Puttini P; Salvarani C; Guiducci S; Zampogna G; Gremese E; Pipitone N; Scrivo R; Bugatti S; Montecucco C; Matucci-Cerinic M;
Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S7-14. PubMed ID: 21906423
[TBL] [Abstract][Full Text] [Related]
8. [Rheumatoid arthritis: milestones in classification and treatment].
Fiehn C
Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
[TBL] [Abstract][Full Text] [Related]
9. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
Emery P; Pope JE; Kruger K; Lippe R; DeMasi R; Lula S; Kola B
Adv Ther; 2018 Oct; 35(10):1535-1563. PubMed ID: 30128641
[TBL] [Abstract][Full Text] [Related]
11. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
12. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Bykerk VP; Akhavan P; Hazlewood GS; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Bombardier C;
J Rheumatol; 2012 Aug; 39(8):1559-82. PubMed ID: 21921096
[TBL] [Abstract][Full Text] [Related]
13. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
14. A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.
Nicholls D; Zochling J; Boers A; Champion G; Mathers D; Riordan J; Youssef P; Scott J; Griffiths H
Int J Rheum Dis; 2014 Sep; 17(7):755-61. PubMed ID: 24131467
[TBL] [Abstract][Full Text] [Related]
15. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.
Kissin EY
Clin Ther; 2014 Jul; 36(7):1114-6. PubMed ID: 24996488
[TBL] [Abstract][Full Text] [Related]
16. Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice.
Bijlsma JW
Pol Arch Med Wewn; 2010 Sep; 120(9):347-53. PubMed ID: 20864908
[TBL] [Abstract][Full Text] [Related]
17. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
18. 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs.
Momen Majumder MS; Hasan ATMT; Choudhury MR; Ahmed S; Miah MT; Amin MR; Shahin MA; Islam A; Shazzad MN; Hassan MM; Ahmedullah AK; Rahman MM; Yesmeen S; Uddin T; Haq SA
Cureus; 2024 Apr; 16(4):e59395. PubMed ID: 38707172
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide.
Massardo L; Suárez-Almazor ME; Cardiel MH; Nava A; Levy RA; Laurindo I; Soriano ER; Acevedo-Vázquez E; Millán A; Pineda-Villaseñor C; Galarza-Maldonado C; Caballero-Uribe CV; Espinosa-Morales R; Pons-Estel BA
J Clin Rheumatol; 2009 Jun; 15(4):203-10. PubMed ID: 19502907
[TBL] [Abstract][Full Text] [Related]
20. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis.
Turkstra E; Ng SK; Scuffham PA
Curr Med Res Opin; 2011 Oct; 27(10):1885-97. PubMed ID: 21848493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
